Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
This article was originally published in The Pink Sheet Daily
Executive Summary
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.